HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 - (ACN Newswire via SEAPRWire.com) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund...

Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 - (ACN Newswire via SEAPRWire.com) - Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the...

Nakamoto Games Entering New Growth Phase

Play-to-earn disruptor to finalize private sale token distribution ahead of schedule Mahe, Seychelles, June 25, 2022 – (SEAPRWire) -Nakamoto Games ($NAKA), the token powering the industry’s fastest-growing play-to-earn gaming ecosystem, is entering a new growth phase with exciting prospects. On Monday, June 27th, 2022, Nakamoto Games will release the last $NAKA token allocation...

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trialsANB032 IND filing in an initial proof-of-concept Phase 2 trial is anticipated in the second half of 2022Imsidolimab (anti-IL-36R Ab) top-line data from the Phase 2...

Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 - (ACN Newswire via SEAPRWire.com) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.Highlights-- The group's turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million;-- Sales coverage increased...

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased...

Some Pavilia Farm concrete samples fail tests: govt

The Buildings Department said on Monday that "a very small portion" of samples from two towers at the Pavilia Farm residential development in Tai Wai have a concrete strength that is lower than approved. The checks were carried out after New World Development announced in July that it was demolishing...

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 30 November...